Abstract: Bioactive peptides are related to the prevention and treatment of many diseases.
[6].
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On the basis of these considerations, bioactive peptides are a short sequence of amino acids with 49 different biological activities. Initially, they are found in a protein precursor in the organism of origin 50 and they are generally not active [7, 8] . The peptide is obtained from plant proteins as a result of 51 enzymatic hydrolysis during digestion, by fermentation in micro-organisms or by in-vitro chemical 52 or enzymatic hydrolysis processes [7] .
53
Lupinus angustifolius L. is one of the targets for the search of this type of peptides because it has a high 54 amount of proteins and low lipids [9, 10] . GPETAFLR is an octapeptide isolated from Lupinus 55 angustifolius L. with sequence Glycine-Proline-Glutamic Acid-Threonine-Phenylalanine-Leucine-
56
Arginine. This peptide features a three-dimensional secondary structure of α-helix (Figure 1) . Its 
73
and Arginine (R). Yellow colour was used to side chain, green colour was used to amino group, and 74 blue colour was used to carboxyl group.
75
Non-alcoholic fatty liver disease (NAFLD) is a health problem that affects a large percentage of the 76 world's population with a global prevalence of 25,24% (14). The prevalence of this disease is very 77 common in developed countries, due to the fact that it typically occurs in people with obesity, type 2 78 diabetes, and metabolic syndrome, among other pathologies related to lifestyle [15] [16] [17] [18] . NAFLD
79
consists of the accumulation of fat in the liver tissue that it is derived from a high amount of free fatty 80 acids (FFA) and triglycerides (TGs) in the circulating blood. These levels may be increased by a higher 81 caloric and fat intake. For this reason, fatty liver disease is often associated with obesity and 82 dyslipemias [15] [16] [17] [18] . The best models for the study of this disease are animal models of induced 83 obesity; specifically, mice and rat models present a pathogenesis more similar to humans [19] .
84
NAFLD has 4 phases, non-alcoholic fatty liver (NAFL), accumulation of fat in the liver; non-alcoholic 85 steatohepatitis (NASH), liver fat accumulation with inflammation; fibrosis, accumulation of fat and 
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The mixture was then heated at 85 °C for 15 min to inactivate the enzyme and centrifuged at 6500 x 109 g for 15 min, and the supernatant constituted LPH [11] . This fraction was purified by ultrafiltration 110 and chromatographic techniques [22] . The sequence of the purified peptide was identified through 111 sequence analysis by the nanoHPLC coupled to a Polaris Q ion-trap mass spectrometer (Mass
112
Spectrometry Unit, Instituto de la Grasa, Seville, Spain). Finally, the peptide was synthesized by Fmoc 
Animal Diets and Experimental Design
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Male mice C57BL/6J were used for the study. They were obtained from the Animal Production and
117
Experimentation Centre at the University of Seville. The mice were divided into four groups in which 118 3 of them were fed with an HFD and the last group was fed with a standard chow diet and was used After 8 weeks of diet, the animals showed a gain in body weight (Figure 2A) , and the increase in 
GPETAFLR decreases hepatic steatosis in HFD-induced obese mice
221
After 8 weeks of HFD, levels of TGs in liver tissue were higher with respect to the CD ( Figure 5A ).
222
However, TG levels were lower in those animals that were fed HFD and received GPETAFLR as 
Discussion
326
The use of bioactive peptides obtained from food is increasingly gaining importance because of its 327 ability to improve human health and prevent chronic diseases, whose incidence is increasing 
334
The liver is the main metabolic organ of the body. NAFLD affects its functionality, endangering the 335 homeostasis metabolic system. This disease is typically associated with obesity [15-18], wherefore a 336 substance which has the effect of reducing body weight and obesity rates will greatly alleviate the 338 resulting from a diet rich in fat in contrast to other substances with hepatoprotective properties that 339 do not have the capacity to prevent weight gain such as isoliquiritigenin [32] . It can be said that
340
GPETAFLR interferes by preventing the progression of the main cause of NAFLD, obesity.
341
On the other hand, the data obtained corroborate that HFD-induced obese mice, presented a NAFLD
342
pathophysiology similar to humans. The physiopathology of this disease is characterized by 343 increased body weight and liver, high levels of TGs in the blood, fat accumulation in adipose tissue,
344
hepatic inflammation and elevated markers of liver damage [33] . In our project, the obese control 345 group showed a greater hepatic weight derived from a greater accumulation of hepatic fat. The 346 accumulation may be due to high levels of TGs in the blood and the increase in FAS gene expression.
347
In addition, this group also presented a pro-inflammatory state, provoked by high levels of 
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All these parameters of the pathology were palliated with the treatment with GPETAFLR, owing to 
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In previous studies, GPETAFLR has been demonstrated to present anti-inflammatory activity that is 
373
GPETAFLR may decrease inflammation by influencing the NF-κB pathway.
374
Another parameter used as a marker of NAFLD pathogenesis in this study was the measurement of 375 blood markers of liver damage, specifically transaminases, ALP, and LDH. The activity of these 376 enzymes in serum was lower in both GPETAFLR treatments compared to the obese control group.
377
This effect is due, probably, to the fact that peptide decreases liver damage by reducing the 378 accumulation of fat and inflammation (influenced by the lower accumulation of fat) and thus all the 379 tissue damage associated with a chronic inflammatory process.
380
On the other hand, leptin is an adipokine produced by adipose tissue, and the levels of this hormone
381
in the blood are indicative of the body's fat reserves, because it is produced proportionally to the 
411
ALT, ALP, and LDH. Taken together, our findings suggest that GPETAFLR is a potential treatment,
412
as well as an important preventive therapy for NAFLD. Thus, the dietary supplementation with
413
Lupinus angustifolius L. would also contribute to a reduction of this pathology.
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Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Table S1 : Sequence and
415
GenBank accession number of oligonucleotides used in RT-qPCR. 
